pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART

Similar Items

• Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.
  by: Guimarães-Walker, A, et al.
  Published: (2008)
• Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers (vol 26, pg 6671, 2008)
  by: Guimaraes-Walker, A, et al.
  Published: (2011)
• Corrigendum to " Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers" [Vaccine 26 (2008) 6671-6677]
  by: Guimarães-Walker, A, et al.
  Published: (2011)
• Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes.
  by: Saubi, N, et al.
  Published: (2011)
• Newborn Mice Vaccination with BCG.HIVA(222) plus MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes
  by: Saubi, N, et al.
  Published: (2011)